

## EPARTMENT OF COMMERCE

**Patent and Trademark Office** 

COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

**DATE MAILED:** 

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/436,184 11/08/99 WANDS J 04930/032001 **EXAMINER** HM22/0427 WILLIAM E BOOTH CANELLA, K FISH & RICHARDSON PC **ART UNIT** PAPER NUMBER 225 FRANKLIN STREET BOSTON MA 02110-2804 1642

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

04/27/00



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DATE MAILED:

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.	
г				
			EXAMINER CANELLA	
		CANELLA		
		ART UNIT	PAPER NUMBER	

## Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

- 1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
- 2. Any inquiry concerning this communication should be directed to Examiner Karen A. Canella, Art Unit 1642, whose telephone number is (703)308-8362.
- 3. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.
- 4. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the∧response.

Karen A. Canella, Ph.D. Patent Examiner, Group 1642

NANCY A. JOHNSON, PH.D. PRIMARY EXAMINER

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION	
NUCLEOTIDE SEQUENCE AND OR AMINO ACID SEQUENCE DISCOSURI	ES CONTAINING
The nucleotide and/or amino acid sequence disclosure contained in the not comply with the requirements for such a disclosure as set forth 1.825 for the following reason(s):	is application does in 37 CFR 1.821 -
1. This application clearly fails to comply with the requires	ments of 37 CFR 1.821
1. This application clearly fails to comply with the required to these regulations, pure may 15, 1990 and at 55 FR 18230, May 1, 1990.	
2. This application does not contain, as a separate part of paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).	the disclosure on
3. A copy of the "Sequence Listing" in computer readable for submitted as required by 37 CFR 1.821(e).	n has not been
4. A copy of the "Sequence Listing" in computer readable form	n has been submitted.
However, the content of the computer readable form does not comply wof 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the Sequence Listing."	with the requirements
5. The computer readable form that has been filed with this	application has been
found to be damaged and/or unreadable as indicated on the attached (Report. A substitute computer readable form must be submitted as real.825(d).	RF Diskette Problem quired by 37 CFR
	en e
6. The paper copy of the "Sequence Listing" is not the same	•
	•
6. The paper copy of the "Sequence Listing" is not the same	•
6. The paper copy of the "Sequence Listing" is not the same	•
6. The paper copy of the "Sequence Listing" is not the same readable form of the "Sequence Listing" as required by 37 CFR 1.821	•
6. The paper copy of the "Sequence Listing" is not the same readable form of the "Sequence Listing" as required by 37 CFR 1.821	•
6. The paper copy of the "Sequence Listing" is not the same readable form of the "Sequence Listing" as required by 37 CFR 1.821	(e).
6. The paper copy of the "Sequence Listing" is not the same readable form of the "Sequence Listing" as required by 37 CFR 1.821.  7. Other:  Applicant must provide:	(e).
6. The paper copy of the "Sequence Listing" is not the same readable form of the "Sequence Listing" as required by 37 CFR 1.821.  7. Other:  Applicant must provide:  An initial or substitute computer readable form (CRF) copy of	the "Sequence
6. The paper copy of the "Sequence Listing" is not the same readable form of the "Sequence Listing" as required by 37 CFR 1.821.  7. Other:  Applicant must provide:  An initial or substitute computer readable form (CRF) copy of Listing"  An initial or substitute paper copy of the "Sequence Listing" amendment directing its entry into the specification	the "Sequence
6. The paper copy of the "Sequence Listing" is not the same readable form of the "Sequence Listing" as required by 37 CFR 1.821(  7. Other:  Applicant must provide:  An initial or substitute computer readable form (CRF) copy of Listing"  An initial or substitute paper copy of the "Sequence Listing"	the "Sequence , as well as an le copies are the san
6. The paper copy of the "Sequence Listing" is not the same readable form of the "Sequence Listing" as required by 37 CFR 1.821(  7. Other:  Applicant must provide:  An initial or substitute computer readable form (CRF) copy of Listing"  An initial or substitute paper copy of the "Sequence Listing" amendment directing its entry into the specification  A statement that the content of the paper and computer readable and, where applicable, include no new matter, as required by	the "Sequence , as well as an le copies are the san 37 CFR 1.821(e) or

Please return a copy of this notice with your response.

For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400